Pharmaceutical Market Survey Report:What does the 2026 Pharmaceutical Market Survey Report reveal about global market growth?

Q: What does the 2026 Pharmaceutical Market Survey Report reveal about global market growth?

A: The 2026 Pharmaceutical Market Survey Report, published by the IQVIA Institute for Human Data Science, projects global medicine spending will reach $2.3 trillion by 2028, growing at a compound annual growth rate of 5–8% through 2028. The report highlights that growth is driven primarily by oncology, immunology, and diabetes therapies, alongside increased demand in emerging markets such as China, India, and Brazil. It also notes that global volume growth will be concentrated in lower-cost generics and biosimilars, while spending growth remains dominated by innovative specialty medicines. The 2026 report further emphasizes that COVID-19-related products will have a diminishing impact on overall market dynamics. According to official IQVIA 2026 data, the United States remains the largest market, accounting for roughly 43% of global spending, followed by China and Europe. The report also warns that pricing pressures and patent expirations will offset some new product launches.

Q: How does the 2026 Pharmaceutical Market Survey Report assess the impact of biosimilars?

A: The 2026 Pharmaceutical Market Survey Report, issued by the IQVIA Institute, states that biosimilars are expected to contribute significantly to savings and access. By 2026, biosimilar competition will have reduced spending on originator biologics by an estimated $180 billion cumulatively since 2020, according to official IQVIA 2026 figures. The report identifies oncology and autoimmune disease areas as the largest sources of biosimilar-driven savings. Europe leads in biosimilar adoption due to supportive regulatory frameworks, while the U.S. market is accelerating following the approval of several high-profile biosimilars. The report also notes that market penetration varies widely by product and country. Additionally, it emphasizes that physician confidence and payer policies remain critical barriers. The 2026 survey recommends that stakeholders focus on education and interchangeability designations to unlock further savings and improve patient access to biologic therapies.

Q: What are the key regional trends in the 2026 Pharmaceutical Market Survey Report?

A: The 2026 Pharmaceutical Market Survey Report from IQVIA highlights divergent regional trends. In the United States, spending growth is projected at 5–8% annually through 2028, driven by specialty medicines and a stable pipeline, though patent expirations will temper growth. China, the second-largest market, is expected to grow at 7–10%, fueled by expanded insurance coverage and local innovation, per official IQVIA 2026 data. Europe shows slower growth of 3–5%, constrained by austerity measures and generic penetration. Emerging markets in Asia, Latin America, and Africa are forecast to grow at 6–9%, supported by rising incomes and infrastructure investment. Japan and South Korea remain innovation-focused but face demographic headwinds. The report also notes that the Middle East and Africa will see increased access through public-private partnerships. Overall, the 2026 report underscores that regional dynamics require tailored strategies from manufacturers and policymakers.

Q: What role does research and development play according to the 2026 Pharmaceutical Market Survey Report?

A: The 2026 Pharmaceutical Market Survey Report, published by the IQVIA Institute, indicates that global R&D spending reached $280 billion in 2025 and is projected to grow 4–6% annually through 2028. The report highlights a shift toward precision medicine, cell and gene therapies, and mRNA platforms. According to official IQVIA 2026 data, the pipeline contains over 10,000 active compounds, with oncology accounting for 40% of late-stage projects. The report notes that R&D productivity has improved modestly, with higher success rates in rare diseases and targeted therapies. However, challenges persist: rising trial costs, complex regulatory requirements, and pricing pressures. The 2026 survey emphasizes that partnerships between biotech and large pharma are crucial to sustain innovation. Additionally, it calls for adaptive trial designs and real-world evidence to accelerate approvals and patient access.

Dialogue about

Common scenarios of "Pharmaceutical Market Survey Report"

【Market Analyst】 Good morning, everyone. Thank you for joining this meeting to discuss the findings of our latest Pharmaceutical Market Survey Report. As you know, we conducted a comprehensive survey across 15 countries over the past six months. Today, I'll present the key insights and then we can dive into implications for our strategy.

【Strategy Director】 Thanks for setting this up. I'm particularly interested in the growth trends in emerging markets and how they compare to mature markets. Can you start with an overview of the global market size and growth rate?

【Market Analyst】 Absolutely. The global pharmaceutical market was valued at approximately $1.5 trillion in 2023 and is projected to grow at a CAGR of 6.5% from 2024 to 2030. Emerging markets like China, India, and Brazil are growing at nearly double that rate, around 11-12%, driven by increasing healthcare access, rising chronic disease prevalence, and government initiatives.

【R&D Manager】 That's impressive growth. What about therapeutic areas? Which segments are driving this expansion? I assume oncology and immunology are still leading?

【Market Analyst】 You're spot on. Oncology remains the largest segment, accounting for about 30% of the market, followed by immunology and diabetes. However, we're seeing significant growth in rare diseases and gene therapies, albeit from a smaller base. The survey also highlighted a surge in demand for mental health drugs, especially post-pandemic.

【Regulatory Affairs Specialist】 That's interesting. With the growth in gene therapies, how are regulatory environments adapting? Our survey should include feedback on approval timelines and hurdles in different regions.

【Market Analyst】 Indeed, we dedicated a section to regulatory landscapes. The FDA and EMA have streamlined pathways for breakthrough therapies, but in emerging markets, approval processes can be slower and less predictable. We found that 60% of respondents in emerging markets cited regulatory delays as a major barrier to market entry.

【Strategy Director】 That's a critical point. We need to factor that into our market entry strategies. What about pricing and reimbursement trends? Are payers becoming more restrictive?

【Market Analyst】 Yes, pricing pressure is intensifying globally. In the US, the Inflation Reduction Act is allowing Medicare to negotiate drug prices, which is a game-changer. In Europe, reference pricing and health technology assessments are common. Our survey shows that 75% of pharmaceutical executives expect increased pricing pressure over the next five years.

【R&D Manager】 Given that, how do we balance innovation with affordability? Are there opportunities in value-based pricing or outcomes-based contracts?

【Market Analyst】 Definitely. We're seeing a shift towards value-based agreements, especially for expensive therapies. For example, in the US, some gene therapies are being priced based on real-world outcomes. Our report includes case studies on this. It's a complex area but offers a way to align payer and manufacturer interests.

【Regulatory Affairs Specialist】 I'd like to add that real-world evidence is becoming more important for regulatory decisions as well. The survey should capture how companies are investing in RWE generation.

【Market Analyst】 Good point. We did include a question on RWE. About 65% of companies said they are increasing investment in RWE to support regulatory submissions and market access. This is particularly true for oncology and rare diseases.

【Strategy Director】 What about the competitive landscape? Are we seeing more consolidation, or are smaller biotechs making a mark?

【Market Analyst】 Both. Mega-mergers continue among big pharma, but biotechs are driving innovation, especially in cell and gene therapy. Our survey indicates that partnerships between big pharma and biotechs are on the rise, with 70% of large companies expecting to increase collaborations with smaller firms.

【R&D Manager】 That aligns with our own experience. We're constantly scouting for promising biotech assets. But what about talent? Is there a shortage of skilled workers in certain areas?

【Market Analyst】 Yes, talent shortage is a significant issue. 80% of survey respondents reported difficulties in hiring for roles in data science, AI, and specialized clinical research. This is a global challenge, but especially acute in emerging markets where competition for talent is fierce.

【Regulatory Affairs Specialist】 How does this impact regulatory submissions? If companies lack expertise, it could lead to delays or rejections.

【Market Analyst】 Exactly. We found a correlation between talent gaps and longer approval times. Companies are addressing this through training programs and outsourcing to CROs, but it's an ongoing challenge.

【Strategy Director】 This has been very insightful. To wrap up, what are the top three strategic recommendations from the report?

【Market Analyst】 First, prioritize emerging markets with tailored strategies, including local partnerships and regulatory navigation. Second, invest in value-based pricing models and RWE to demonstrate value. Third, address talent gaps through upskilling and strategic collaborations. I'll share the full report with you all, and we can discuss action plans in the next meeting.

【Strategy Director】 Thank you. That gives us a clear direction. Let's reconvene next week to develop a roadmap based on these findings.